Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* YANCOPOULOS GEORGE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [ REGN ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President and Chief Scientific
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD	3. Date of Earliest Transaction (MM/DD/YYYY) 6/21/2021
(Street) TARRYTOWN, NY 10591 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	1/12/2021		G	V	82108	A	$0.0	82108	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		738	D	$532.89 ⁽³⁾	81370	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		7494	D	$533.66 ⁽⁴⁾	73876	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		8236	D	$534.48 ⁽⁵⁾	65640	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		4154	D	$535.63 ⁽⁶⁾	61486	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		3768	D	$536.37 ⁽⁷⁾	57718	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		6636	D	$537.61 ⁽⁸⁾	51082	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		4868	D	$538.54 ⁽⁹⁾	46214	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		3306	D	$539.66 ⁽¹⁰⁾	42908	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		8099	D	$540.61 ⁽¹¹⁾	34809	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		19911	D	$541.44 ⁽¹²⁾	14898	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		10514	D	$542.43 ⁽¹³⁾	4384	I	By Trust for Chldn. ⁽¹⁾
Common Stock	6/21/2021		S⁽²⁾		2276	D	$543.13 ⁽¹⁴⁾	2108	I	By Trust for Chldn. ⁽¹⁾
Common Stock								987483	D
Common Stock								5845	I	By 401(k) Plan
Common Stock								211585	I	by 2019 GRAT

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Stock	⁽¹⁵⁾	4/15/2021		G		14000		⁽¹⁶⁾	⁽¹⁶⁾	Common Stock	14000	$0.0	14000	I	By Tr. for Daughter ⁽¹⁷⁾
Class A Stock	⁽¹⁵⁾	4/15/2021		G			14000	⁽¹⁶⁾	⁽¹⁶⁾	Common Stock	14000	$0.0	0	I	by Daughter ⁽¹⁸⁾
Class A Stock	⁽¹⁵⁾	4/15/2021		G			5383	⁽¹⁶⁾	⁽¹⁶⁾	Common Stock	5383	$0.0	0	I	by Son ⁽¹⁸⁾
Class A Stock	⁽¹⁵⁾	4/15/2021		G		5383		⁽¹⁶⁾	⁽¹⁶⁾	Common Stock	5383	$0.0	5383	I	by Trust for Son ⁽¹⁷⁾

Explanation of Responses:
(1)	As investment trustee of trusts for the benefit of the reporting person's children.
(2)	Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(3)	Represents volume-weighted average price of sales of 738 shares of Company stock on June 21, 2021 at prices ranging from $532.56 to $532.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(4)	Represents volume-weighted average price of sales of 7,494 shares of Company stock on June 21, 2021 at prices ranging from $533.14 to $533.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(5)	Represents volume-weighted average price of sales of 8,236 shares of Company stock on June 21, 2021 at prices ranging from $534.01 to $534.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(6)	Represents volume-weighted average price of sales of 4,154 shares of Company stock on June 21, 2021 at prices ranging from $535.05 to $535.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(7)	Represents volume-weighted average price of sales of 3,768 shares of Company stock on June 21, 2021 at prices ranging from $536.02 to $536.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(8)	Represents volume-weighted average price of sales of 6,636 shares of Company stock on June 21, 2021 at prices ranging from $537.05 to $537.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(9)	Represents volume-weighted average price of sales of 4,868 shares of Company stock on June 21, 2021 at prices ranging from $538.01 to $538.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(10)	Represents volume-weighted average price of sales of 3,306 shares of Company stock on June 21, 2021 at prices ranging from $539.14 to $539.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(11)	Represents volume-weighted average price of sales of 8,099 shares of Company stock on June 21, 2021 at prices ranging from $540.00 to $540.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(12)	Represents volume-weighted average price of sales of 19,911 shares of Company stock on June 21, 2021 at prices ranging from $541.00 to $541.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(13)	Represents volume-weighted average price of sales of 10,514 shares of Company stock on June 21, 2021 at prices ranging from $542.00 to $542.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(14)	Represents volume-weighted average price of sales of 2,276 shares of Company stock on June 21, 2021 at prices ranging from $543.01 to $543.46. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 21, 2021 at each separate price.
(15)	Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder.
(16)	These shares of Class A Stock are presently convertible and such conversion feature does not expire.
(17)	These shares of Class A Stock are held in a trust for the benefit of the reporting person's child, of which the reporting person is trustee.
(18)	These shares of Class A Stock were held in custody for the benefit of the reporting person's child.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
YANCOPOULOS GEORGE 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591	X		President and Chief Scientific